By Joshua Kirby

 

Sanofi SA said Friday that its coronavirus booster vaccine, developed alongside Britain's GSK PLC, has produced successful results against the Omicron variant of the coronavirus in an efficacy study.

The French biopharmaceutical company said its vaccine candidate showed efficacy against the virus in an environment of high Omicron variation. It showed 72% efficacy against the strain in adult, as well as a favorable safety and tolerability profile, the company said.

Along with positive data from two previous trials, the results will be submitted to regulatory authorities for approval, Sanofi said.

The results "indicate the potential of Sanofi-GSK's next-generation Beta-based booster to be a relevant response to public health needs," the company said.

 

Write to Joshua Kirby at joshua.kirby@wsj.com; @joshualeokirby

 

(END) Dow Jones Newswires

June 24, 2022 02:06 ET (06:06 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Gsk Charts.
Gsk (LSE:GSK)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Gsk Charts.